INTRODUCTION 56
Miltefosine is currently the only oral drug available for the treatment of visceral 57 first-order absorption and elimination from the central compartment, which was 132 estimated and validated from previous miltefosine pharmacokinetic data from Indian 133 individuals, 18 was used for the simulations. To account for the effects of body size on 134 the pharmacokinetics of miltefosine, allometric scaling of clearance and volume of 135 distribution by fat-free mass was applied, since this was previously validated as the 136 best body size model and descriptor for miltefosine over a wide range of body sizes. because pharmacokinetic parameters were normalized to this value); and PWR is the 146 allometric power exponent, which was fixed for clearance at 0.75 and for volume of 147 distribution at 1.0, based on the biological principles that support these values.
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The following estimates for the parameters that were previously estimated were fixed 149 in the simulations and are summarized in Table 1 . Bioavailability (F) was unknown, 150 and therefore, parameters relative to the bioavailability were used (CL/F, V/F, etc.). 151
152
Simulated miltefosine dose regimens 153
Several lengths or durations of miltefosine treatment were simulated individually (as 154 described above) for the selected Indian female VL patients of child-bearing potential.
These Monte Carlo random pharmacokinetic simulations were repeated 100 times. 156
The absolute daily dose (mg/day) was similar between these regimens, conform the 157 current guidelines for miltefosine usage in India: individuals with a body weight below 158 25 kg were allocated to receive 50 mg miltefosine once daily; while individuals with a 159 body weight ≥ 25 kg were allocated to receive 50 mg twice daily with a 12 hour 160 interval, which is a total of 100 mg/day. 7 Treatment durations of 5, 7, 10 and 28 days 161 were separately simulated. 162
163
Conversion of drug dose from animal to human and definition of a 164 reproductive safety threshold exposure limit 165 The no observed adverse effect level (NOAEL) of miltefosine, for which specifically no 166 reproductive toxicity in the most sensitive animal test species (the rat) was observed, 167 was determined from previous preclinical teratogenicity, foeto-and embryotoxicity 168 studies. This NOAEL was translated to a total human equivalent dose using the dose 169 calculator tool available through the FDA. 23 Basically, the total dose per body weight 170 in rats (mg/kg) was recalculated to a total dose per body surface area (BSA) in rats 171 (mg/m 2 ) using a default rat body weight of 0. Where HED is the total human equivalent dose and WT human and HT human are the 179 median weight (g) and height (cm), respectively, of Indian female VL patients of 180 child-bearing potential in the anthropometric database (MSF-OCBA). 181
Miltefosine drug exposure (area under the curve from zero to infinity, AUC 0-∞ ) 182 following administration of the total NOAEL human equivalent dose in a population of 183
Indian females of child-bearing potential was simulated as described above. Based on 184 these simulations, a reproductive safety threshold exposure limit for miltefosine in 185 human was defined as the median miltefosine exposure following administration of 186 the total NOAEL human equivalent dose. To account for any unknown difference in 187 sensitivity to the reproductive toxicity of miltefosine between human and the animal 188 test species, the reproductive safety threshold exposure limit was divided by a default 189 animal-to-human uncertainty factor of 10.
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Probability of exposure above the reproductive safety threshold exposure 192
The 'unprotected' residual exposure to miltefosine after end of the contraceptive 194 cover period until infinity (depicted schematically in 
RESULTS
214
Anthropometric data 215
The anthropometric dataset of VL patients from Bihar provided by MSF-OCBA 216 contained 2264 individuals of which 465 were eligible females of child-bearing 217 potential (≥12 years and ≤45 years). The most salient demographic characteristics of 218 the selected female VL patients of child-bearing potential are depicted in Table 2 . 219 220
Population pharmacokinetic Monte Carlo simulations 221
Of the 465 selected women, only 21 (4.5%) had a body weight lower than 25 kg and 222
were allocated a miltefosine dosage of 50 mg once daily, while the other women were 223 allocated a dosage of 50 mg twice daily, according to the standard miltefosine 224 treatment guidelines in India. 7 The mean daily miltefosine dosage per kg of body 225 weight was 2.37 mg/kg (range 2.08-2.63 mg/kg) for body weights below 25 kg and 226 2.67 mg/kg (range 1.42-4.00 mg/kg) for body weights equal or above 25 kg. 227
For each individual a pharmacokinetic curve was simulated for miltefosine for each of 228 the four different treatment lengths (5, 7, 10 and 28 days). Visual predictive checks 229 (Figure 2 ) extracted from these simulations (n = 465 x 100) depict the median 230 concentrations during and after treatment and the 90% prediction interval for the 231 respective dose regimens. Simulated miltefosine plasma concentrations at various 232 time points after start of treatment were evaluated and are shown in Table 3 . 233
Additionally, the time until the simulated miltefosine plasma concentration curves 234 reached the lower limit of quantitation of the currently most sensitive detection 235 method for miltefosine in human plasma (4 ng/mL), 32 i.e. miltefosine concentrations 236 would become undetectable, was for the 5, 7, 10 and 28 day regimens after a median 237 In reproductive animal studies, oral doses of 1.2 mg/kg/day and above given for 10 243 days to pregnant rats minimally led to teratogenicity, the maximal miltefosine dose 244 that caused no reproductive toxicity (NOAEL) was therefore 0.6 mg/kg/day.
3,33,34
245
Given the pharmacokinetic properties of miltefosine, with an extremely long primary 246 and terminal elimination half-life and thus a high accumulation of subsequent 247 dosages, a single total dose of miltefosine was regarded as equivalent in terms of 248 total exposure to the same total dosage divided over e.g. 10 days. Therefore, in rat 249 (body weight and BSA fixed at 0.15 kg and 0.025 m 2 , respectively), a repeated 250 miltefosine dose of 0.6 mg/kg/day for 10 days corresponds to a total dose of 0.9 mg 251 or 36 mg/m 2 in rats. Converting this NOAEL BSA-normalized dose to a human 252 equivalent dose (body weight and height fixed at 38 kg and 148 cm, respectively), a 253 36 mg/m 2 dose would result in a total single human equivalent dose of 45 mg, which 254 corresponds to 50 mg if rounded to the nearest miltefosine capsule unit. The median 255 AUC 0-∞ (90% prediction interval) following administration of 50 mg in the selection of 256
Indian female VL patients of child-bearing potential (n = 465) was 245 µg*day/mL 257 (140 -467 µg*day/mL). Divided by an animal-to-human uncertainty factor of 10, the 258 reproductive safety threshold exposure limit was identified at 24.5 µg*day/mL. 259 260 Probability of exposure above the reproductive safety threshold exposure 261 limit 262
Using the simulated individual pharmacokinetic curves for different miltefosine 263 regimens (5, 7, 10 and 28 days) as described above, the miltefosine exposure after 264 the end of different contraceptive cover durations until infinity (AUC EOC-∞ ) was 265 analyzed ( Table 4 and Figure 1 ). The probability for the simulated Indian female VL 266 patients of child-bearing potential of having a post-contraceptive (or 'unprotected') 267 exposure to miltefosine higher than the identified reproductive safety threshold 268 exposure limit is shown in Table 5 . A 1 month period of contraceptive cover after 269 end of treatment led to 'unprotected' exposure to miltefosine exceeding the threshold 270 exposure limit in a proportion of simulated females in all treatment regimes. For the 271 5 and 7 day regimens, 2 months of contraceptive cover after cessation of treatment 272 were sufficient to reduce the probability of having a supra-threshold miltefosine 273 exposure to <0.1 %, while for the 10 and 28 day regimen 3 and 4 months of 274 contraceptive cover, respectively, were needed to reach <0.1% probability ( Table  275 5). 276
277
CONCLUSION AND DISCUSSION 278
To our knowledge, this is the first study that provides suggestions for contraceptive 279 cover for a potentially teratogenic drug based on dose conversion from preclinical 280 teratogenicity studies to human. A reproductive safety threshold exposure limit wasdefined for miltefosine based on the conversion of the NOAEL dose in animal 282 reproductive toxicity studies to human. Miltefosine exposure was simulated for Indian 283 female VL patients of child-bearing potential following treatment with different 284 miltefosine regimens making use of a large comprehensive dataset of anthropometric 285 data for Indian VL patients and population pharmacokinetic Monte Carlo simulations. 286
Probability analysis of supra-threshold exposure to miltefosine suggested a period of 287 contraceptive cover after cessation of treatment of 2 months for a 5, 7 or 10 day 288 miltefosine regimen and 4 months for a standard 28 day miltefosine regimen. 289
290
The design of teratogenic risk management-programmes and -strategies for drugs 291 exhibiting reproductive toxicity in preclinical studies is problematic, often lacking 292 rational considerations and usually not taking into account any actual data from 293 preclinical studies. Human maternal or foetal pharmacokinetic data are very rarely 294 available for those compounds, which could facilitate the estimation of a minimal 295 human teratogenic effect level of the drug. Even animal pharmacokinetic data from 296 reproductive toxicity studies are most often lacking or at least not made publicly 297 available, complicating extrapolation of the teratogenic dose-effect relationship. 35 
298
Theoretical physiological or pharmacokinetic considerations are sometimes included 299 in these risk-management strategies. For ribavirin, an antiviral drug used in the 300 treatment of hepatitis C infections, a 6 month period of contraceptive cover after 301 cessation of therapy is recommended based on the turnover time of erythrocytes in 302 which the drug tends to accumulate.
36,37 For isotretinoin, a vitamin A derivative used 303 in the treatment of cystic acne vulgaris, the time until (endogenous) retinoic acid 304 levels have returned to normal after end of treatment is taken as directive to define 305 the reproductive safety period.
38-41 Another related approach is based on the time 306 needed until the drug becomes undetectable in plasma, which is used e.g. forleflunomide, a pyrimidine synthesis inhibitor in the treatment of rheumatoid 308 arthritis. [42] [43] [44] Several disadvantages are associated with this latter approach. Firstly, 309
with inevitably increasing sensitivity of analytical techniques and equipment, the time 310 period until the drug becomes undetectable will increase simultaneously and thus 311 recommendations based on this approach are inclined to change over time. Secondly, 312
317
Approaches for the definition of reproductive safety periods incorporating data from 318 preclinical reproductive toxicity studies in animals and making use of translational 319 pharmacokinetic modelling and simulation have rarely been reported. Physiologically 320 based pharmacokinetic (PBPK) modelling has been applied in reproductive toxicology 321 in both animals and humans to predict e.g. foetal exposure and lactational transfer, 322 but have rarely been used in the development of teratogenic risk management-323 strategies of drugs. [45] [46] [47] In the current study, the NOAEL dose in animal reproductive 324 studies was used to determine a reproductive safety threshold exposure limit for 325 miltefosine in human. Modelling and simulation (M&S) allowed us to assess non-326 parametric probability estimations in the population taking into account the full 327 variability profile of the pharmacokinetics of miltefosine. Simple extrapolation of the 328 point estimates of the drug elimination half-life does not allow for these probability 329 estimations and plausibly leads to underestimation of probability and thus associated 330 risks. The M&S technique that was demonstrated here, therefore, provides a more 331 rational approach to suggest a contraceptive cover period after cessation of therapy. 332
The suggestions following from this analysis might be instrumental in deciding howlong and which contraceptive cover methods are to be implemented in miltefosine 334 treatment guidelines. 335 336 Nevertheless, these suggestions should also be interpreted with caution because of 337 some important study assumptions and limitations. First, determination of the 338 maximal safe miltefosine dose in pregnant female rats was previously performed in a 339
small set of animals and should be regarded as presumptive evidence, which is 340 actually a more general limitation of preclinical reproductive toxicity studies. On the 341 other hand, dose administration in teratogenicity studies was performed for an 342 extended critical period of time during gestation taking into account worst-case 343 scenarios.
3 Additionally, a default well-supported animal-to-human uncertainty factor 344 of 10 was applied.
25,30,31 Second, it must be considered that animal dose regimens 345 remain difficult to extrapolate to human without any further data on miltefosine 346 pharmacokinetics in either pregnant animals or human, although there is no current 347 evidence that miltefosine distribution and metabolism, mainly through 348 phospholipases, is significantly different in any other animal species compared to 349 human.
3,48 Nevertheless, the probability analysis presented here could have been 350 improved significantly if more preclinical data on foetal or maternal drug levels of 351 miltefosine in the reproductive toxicity studies in animals would have been available 352 to incorporate into a PBPK model. This would have allowed the extrapolation of a 353 concentration-effect relationship, in contrast to the more indirect and less accurate 354 dose-effect relationship that was applied here. It might therefore be recommended to 355 emphasize the need for additional pharmacokinetic data collection in reproductive 356 studies in animals for this specific purpose in regulatory guidelines. 49 Third, the 357 pharmacokinetic model that we employed in this study was previously estimated from 358 data from European adult males, Indian adult males and Indian children. It remains complicated to define the adequacy of contraceptive cover periods based 368 on the calculated probability of having a post-contraceptive exposure above the 369 identified reproductive safety threshold exposure limit. The general incidence rate for 370 congenital malformations or anomalies should to be taken into account as well, since 371 this is defined by various (unknown) cumulative genetic and environmental risk 372 factors. In India, the overall incidence of congenital malformation appeared to range 373 between 0.3% and 3.6%.
50, 51 In Europe, a more accurate overall incidence of 2.44% 374 was reported, 52 which may be explained by a higher autopsy rate in the included 375 European centres. Around ~10% of congenital malformations are environmentally 376 induced. 53 To define contraceptive adequacy, it might therefore be appropriate to set 377 the acceptable upper limit of probability for supra-threshold miltefosine exposure at 378 1/10 th of the overall congenital malformation rate, which is 0.244%. With this 379 assumption these findings would support adequate contraceptive cover after 380 cessation of treatment of 2 months for a 5, 7 and 10 day miltefosine regimen and 4 381 months for the standard 28 day miltefosine regimen (Table 5) . Most notably, this 382 suggested post-treatment contraceptive cover period for the 28 day regimen is longer 383 than the currently advised period of 2 or 3 months.
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An additional important factor that needs to be taken into account will be the type of 386 contraceptive cover. Tools such as barrier contraception and the oral contraceptive 387 pill may not be adequate due to low compliance or diminished efficacy (e.g. due to 388 vomiting resulting from miltefosine use). Other forms of contraception such as 389 implants, intra-uterine devices or sterilisation may be too long for the period of cover 390 54 Although nothing is known about sperm count and 405 quality in these patients, this finding does clearly point at effects of miltefosine on the 406 male reproductive system. In order to fully evaluate the appropriateness of 407 recommending additional male contraceptive measures such as barrier protection and 408 counselling during and after miltefosine treatment, more data are needed on the 409 mechanisms of male-mediated reproductive toxicity of miltefosine in e.g. animalstudies and seminal DNA quality of male patients during and after treatment should 411 be better evaluated. 412
413
In conclusion, we here provide suggestions for contraceptive cover periods and 414 associated risks of drug exposure after cessation of therapy for females of child-415 bearing potential treated with different miltefosine regimens based on translation of 416 the minimal safe dose in reproductive toxicity studies in animals to a reproductive 417 safety threshold exposure limit in human. For the standard 28 day miltefosine 418 regimen, the duration of post-treatment contraceptive cover may be extended to 4 419 months. The periods that we suggest take into account worst-case scenarios and 420 might support a more rational teratogenic risk management strategy for miltefosine 421 than currently is the case. 422
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428
FUNDING 429
This study was carried out as part of our routine work. Thomas The miltefosine exposure (1) during treatment with contraceptive cover is indicated in 645 white, (2) after end of treatment (EOT) but still with contraceptive cover in light grey 646 and (3) after end of treatment and after end of contraception in dark grey. In this 647 study we focused on the miltefosine area under the curve from the end of 648 contraception (EOC) until infinity (AUC EOC-∞ ) for different durations of miltefosine 649 treatment and different durations of contraceptive cover period.
